MannKind Data Reveals Afrezza’s 50% Early Effect and Pediatric Approval Insights
MNKD•MannKind presented new data on Afrezza after FDA approved use in patients aged 6+ on May 29, showing non-inferior HbA1c ≤9.5% and over 50% pharmacodynamic effect within 60 minutes versus 10% for lispro. Gestational diabetes and AID analyses showed fewer hypoglycemic events and algorithm-dependent A1C reductions.
1. FDA Approval Expansion and Pediatric Results
MannKind secured FDA approval for Afrezza use in patients aged 6+ on May 29, 2026 and presented INHALE-1 findings showing non-inferior mean HbA1c ≤9.5% in youth over 26 weeks, comparable time-in-range to rapid-acting analogs and higher treatment satisfaction reported by participants and parents.
2. Gestational Diabetes Analysis
An interim gestational diabetes trial indicated Afrezza’s inhaled insulin delivered comparable efficacy to rapid-acting analogs with nominally lower postprandial glucose excursions and fewer hypoglycemic events during standardized meal challenges, supporting its potential as an alternative therapy in GDM.
3. Automated Delivery and Pharmacodynamic Profile
Exploratory evaluations combining Afrezza with automated insulin delivery systems revealed that systems not reliant on total daily dose algorithms achieved numerically greater A1C reductions, while euglycemic clamp data showed over 50% of Afrezza’s action occurs within 60 minutes versus 10% for insulin lispro.
4. Real-World Evidence and Market Access
Real-world assessments reported no increased lung cancer risk among inhaled insulin users and an increase in Medicare Part D utilization following the insulin cost cap, highlighting both safety and improved access that could drive broader adoption.
